ICU Medical/$ICUI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ICU Medical

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Ticker

$ICUI
Sector
Primary listing

Employees

15,000

ICU Medical Metrics

BasicAdvanced
$3.2B
-
-$1.51
0.88
-

What the Analysts think about ICU Medical

Analyst ratings (Buy, Hold, Sell) for ICU Medical stock.

Bulls say / Bears say

ICU Medical’s Q2 2025 revenue reached $548.87 million, beating the $542.50 million consensus, and adjusted EPS was $2.10, surpassing expectations by $0.60, showing strong operational performance (Reuters)
In Q1 2025, consumables revenue increased 9.1% to $266.2 million and infusion systems revenue rose 5.7% to $166.3 million year-over-year, indicating ongoing demand in core markets (Form 10-Q, June 30 2025) (SEC)
GAAP gross margin improved to 35% in Q1 2025 from 33% in Q1 2024, signaling efficiency gains before the IV Solutions joint venture closing (GlobeNewswire)
Vital Care segment revenue fell 34% year-over-year in Q2 2025 after the deconsolidation of the Otsuka joint venture, pointing to structural challenges in a key business line (Investing.com)
The U.S. Food and Drug Administration sent a warning letter in April 2025 regarding unauthorized changes to Medfusion and CADD infusion pumps, introducing regulatory risk and the possibility of enforcement actions for ICU Medical (MedTech Dive)
ICU Medical narrowed its full-year 2025 adjusted EPS guidance to $6.85–$7.15, signifying limited earnings visibility as tariff issues and ongoing integration challenges persist (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

ICU Medical Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ICU Medical Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ICUI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs